SourceBio International plc
(“SourceBio”, the “Company” or the “Group”)
SourceBio International plc (AIM: SBI), an international provider of integrated state-of-the-art laboratory services and products, announces it will present at the Shares Investor Evening Webinar, providing an overview of the business and progress being made by the Company.
Jay LeCoque, Executive Chairman, will present online at the Shares Spotlight webinar on Wednesday 20 January 2021. The event starts at 18.00 and Jay will start presenting promptly at approximately 19.20. The event attracts investors to companies across various sectors and welcomes existing investors along with those looking for new investment opportunities. Investors can register to attend here: https://bit.ly/3sjqqiI
No new material information will be disclosed at the event and the presentation will be made available on the Company website shortly after the events here: https://sourcebioscien.wpengine.com/corporate-presentation-confirmation/
SourceBio International plc
|Jay LeCoque, Executive Chairman||
Via Walbrook PR
|Tony Ratcliffe, Chief Financial Officer|
Walbrook PR Limited
Tel: 020 7933 8780 or email@example.com
|Paul McManus / Sam Allen||
Mob: 07980 541 893 / 07748 651 727
About SourceBio International plc www.sourcebiointernational.com
SourceBio is a leading international provider of integrated state-of-the-art laboratory services and products clients in the healthcare, clinical, life science research and biopharma industries, with a focus on improving patient diagnosis, management and care. Group revenues are derived from four core businesses areas:
- Healthcare Diagnostics – histopathology and clinical diagnostic services for the NHS and private healthcare across the UK and Ireland.
- Genomics – DNA sequencing services for pharmaceutical and biotechnology companies, academia, contract research organisations (CROs) and other research groups in the UK, Europe and North America.
- Stability Storage – shelf-life testing services and equipment for pharmaceutical and biotechnology companies, contract manufacturers and analytical testing companies from around the world but primarily in the UK, Ireland and the USA; and
- Infectious Disease Testing – since May 2020, the Group has provided COVID-19 Antigen RT-PCR testing services. These services passed all of the auditing requirements of the NHS and the Department of Health and Social Care (DHSC) in April 2020. It is intended that this offering will potentially provide a broad range of infectious disease testing across the NHS, private healthcare and commercial sectors in the future.
More details on Group operations can be found here: www.sourcebioscience.com
SourceBio International plc (SBI.L) is listed on the AIM market of the London Stock Exchange.